Cover Image

Evaluation of claims‐based computable phenotypes to identify heart failure patients with preserved ejection fraction

Abstract The purpose of this analysis was to develop and validate computable phenotypes for heart failure (HF) with preserved ejection fraction (HFpEF) using claims‐type measures using the Rochester Epidemiology Project. This retrospective study utilized an existing cohort of Olmsted County, Minneso...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sarah S. Cohen (Author), Véronique L. Roger (Author), Susan A. Weston (Author), Ruoxiang Jiang (Author), Naimisha Movva (Author), Akeem A. Yusuf (Author), Alanna M. Chamberlain (Author)
Format:	Book
Published:	Wiley, 2020-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pediatric heart failure with preserved ejection fraction, a review
by: Sophie Quennelle, et al.
Published: (2023)

THE ROLE OF FACTORS AFFECTING THE FORMATION OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION
by: M. V. Kurkina, et al.
Published: (2017)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
by: James P. Teuber, et al.
Published: (2022)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021)

The oxytocin-oxytocin receptors system - a new pathogenetic mechanism in the development of diabetic phenotype of heart failure with preserved ejection fraction in women
by: A. D. Starchenko, et al.
Published: (2024)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024)

Association Between Hyperaldosteronemia and Electrophysiological Myocardial Activity in Heart Failure with Preserved Ejection Fraction
by: A. N. Shevelok
Published: (2020)

DIASTOLIC LEFT VENTRICULAR DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN ELDERLY
by: CALENICI Oleg, et al.
Published: (2022)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
by: Artem Ovchinnikov, et al.
Published: (2022)

Mitochondrial Reactive Oxygen Species Dysregulation in Heart Failure with Preserved Ejection Fraction: A Fraction of the Whole
by: Caroline Silveira Martinez, et al.
Published: (2024)

Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction
by: Z. M. Akhilgova, et al.
Published: (2020)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction
by: Alexandrina Campos-Martins, et al.
Published: (2021)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023)

Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function
by: Thomas A. Mavrakanas, et al.
Published: (2019)

Heart Failure with Preserved Ejection Fraction in a Postpartum Patient with Superimposed Preeclampsia and COVID-19
by: Rachel G. Sinkey, et al.
Published: (2020)

Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis
by: Marlies Antlanger, et al.
Published: (2017)

Prognostic of NT-proBNP in heart failure patients with preserved, mid and reduced ejection fraction
by: Reynie Leonel Reinoso Gonella, et al.
Published: (2021)

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
by: Liyun Zhang, et al.
Published: (2021)

Subclinical Hypothyroidism Predicted Adverse Cardiovascular Events in Patients with Ejection Fraction Preserved Heart Failure
by: Tan Q, et al.
Published: (2024)

Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction
by: Natasha Fillmore, et al.
Published: (2018)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022)

Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis
by: Zhu Chen, et al.
Published: (2022)

Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms
by: Yujian Fan, et al.
Published: (2023)

A comprehensive evaluation of heart failure with preserved ejection fraction and the relationship to atrial fibrillation in Turkey
by: Muhammed Keskin
Published: (2020)

Prognostic Value of Inflammatory Cytokines in Predicting Hospital Readmissions in Heart Failure with Preserved Ejection Fraction
by: Zhao Z, et al.
Published: (2024)

Resistant Hypertension From Renal Artery Stenosis Leading to Heart Failure With Preserved Ejection Fraction
by: Motasem Alyamani MBBS, et al.
Published: (2018)

ATRIAL FIBRILLATION AND ARTERIAL HYPERTENSION: GENDER DIFFERENCES OF VENTRICULOATRIAL REMODELING WITH PRESERVED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2017)

NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS
by: O. M. Drapkina, et al.
Published: (2015)

Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
by: Xiao Wang, et al.
Published: (2024)

Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations
by: Dzhioeva O, et al.
Published: (2020)

Corrigendum: Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
by: Liyun Zhang, et al.
Published: (2022)

NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS
by: O. M. Drapkina, et al.
Published: (2015)

Cardiac Amyloidosis - An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction - Updated Diagnosis and Treatment Options
by: Roxana Cristina RIMBAS, et al.
Published: (2021)

Assessing cardiac contractility in hypertension with heart failure with preserved ejection fraction: the value of left ventricular strain
by: Simon W. Rabkin
Published: (2023)

Health-related quality of life among congestive heart failure patients with preserved and reduced ejection fraction
by: Hudiyawati Dian, et al.
Published: (2024)

Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center
by: Bradley D, et al.
Published: (2019)